Expression of unfolded protein response genes in post-transplantation liver biopsies

Xiaoying Liu1*, Sarah A. Taylor2, Stela Celaj1, Josh Levitsky1 and Richard M. Green1

Abstract

Background: Cholestatic liver diseases are a major source of morbidity and mortality that can progress to end-stage liver disease and hyperbilirubinemia is a hallmark of cholestasis. There are few effective medical therapies for primary biliary cholangitis, primary sclerosing cholangitis and other cholestatic liver diseases, in part, due to our incomplete understanding of the pathogenesis of cholestatic liver injury. The hepatic unfolded protein response (UPR) is an adaptive cellular response to endoplasmic reticulum stress that is important in the pathogenesis of many liver diseases and recent animal studies have demonstrated the importance of the UPR in the pathogenesis of cholestatic liver injury. However, the role of the UPR in human cholestatic liver diseases is largely unknown.

Methods: RNA was extracted from liver biopsies from patients after liver transplantation. RNA-seq was performed to determine the transcriptional profile and hepatic UPR gene expression that is associated with liver injury and cholestasis.

Results: Transcriptome analysis revealed that patients with hyperbilirubinemia had enhanced expression of hepatic UPR pathways. Alternatively, liver biopsy samples from patients with acute rejection had enhanced gene expression of LAG3 and CDK1. Pearson correlation analysis of serum alanine aminotransferase, aspartate aminotransferase and total bilirubin levels demonstrated significant correlations with the hepatic expression of several UPR genes, as well as genes involved in hepatic bile acid metabolism and inflammation. In contrast, serum alkaline phosphatase levels were correlated with the level of hepatic bile acid metabolism gene expression but not liver UPR gene expression.

Conclusions: Overall, these data indicate that hepatic UPR pathways are increased in cholestatic human liver biopsy samples and supports an important role of the UPR in the mechanism of human cholestatic liver injury.

Keywords: ER stress, Cholestasis, Hyperbilirubinemia, Transcriptome

Background

Cholestatic liver diseases including primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), biliary atresia and familial genetic etiologies remain a major source of significant morbidity and mortality. They are often associated with hyperbilirubinemia. Unfortunately, there are few effective medical therapies for PBC, and no effective medical therapies for PSC and many genetic cholestatic liver disorders, and liver transplantation is the only life-saving option for end-stage diseases [1, 2]. In addition, following liver transplantation, patients with certain cholestatic liver diseases can have significant post-transplantation recurrence rates, with rates of up to 53% in PBC and up to 45% in PSC [2–6]. Post-transplantation liver disease recurrence may result in patient graft loss or death. A major reason for the lack of effective medical therapies for cholestatic liver disorders is our incomplete understanding of the disease pathogenesis and progression. Recent human and animal studies indicate that the liver unfolded protein response (UPR) is

*Correspondence: xiaoying-liu@northwestern.edu
1 Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Full list of author information is available at the end of the article
important in the pathogenesis of cholestatic liver injury and may be prognostic for liver-related complications in patients with PSC [7–9].

The UPR is an adaptive cellular response to endoplasmic reticulum (ER) stress. ER stress is a form of cellular stress that occurs due to an accumulation of excess unfolded or misfolded proteins in the ER. Since protein synthesis in the liver is quantitatively high, it may be particularly susceptible to the development of ER stress [10, 11]. The UPR functions to reduce the number of cellular misfolded or unfolded proteins by enhancing protein folding, attenuating protein translation, and increasing endoplasmic reticulum-associated protein degradation. However, if ER stress is severe and cannot be resolved, it activates apoptosis pathways. The UPR is comprised of three signaling pathways including inositol requiring enzyme 1α/X-box binding protein 1 (XBP1), PKR-like ER kinase (PERK) and activating transcription factor 6 (ATF6), that regulate downstream UPR genes to return cellular homeostasis [12, 13]. The hepatic UPR is important in the pathogenesis of many liver diseases including viral hepatitis, non-alcoholic fatty liver disease, alpha-1 antitrypsin deficiency, alcoholic liver disease and ischemia–reperfusion injury [9–11]. Finally, in a recent study of PSC patients, differential expression of UPR genes was identified in patients who were at high risk for liver-related complications [7]. Unfortunately, the role of the UPR in human cholestasis and cholestatic liver injury remains poorly understood. In order to better determine the role of the hepatic UPR in the pathogenesis of human liver disease, we performed transcriptome analysis on “for-cause” (clinically-indicated for graft injury/dysfunction) liver biopsies from liver transplant recipients and sought to determine how changes in hepatic UPR gene may be associated with liver injury and cholestasis in a post-transplantation setting.

Methods

Human samples

Twenty liver transplant recipients (2013–2015) undergoing a for-cause liver biopsy at Northwestern Memorial Hospital consented to have a portion of their liver biopsy utilized for this study. Briefly, liver biopsy was performed with a 16 gauge 33 mm BioPince needle. If adequate sample size was obtained (>2 cm) for routine histology, a 0.5–1 cm piece was removed from the end of the main piece, placed in RNAlater and stored at −80 °C. Patient demographics, laboratory tests, medication, and clinical data were collected and utilized from the Northwestern Medicine Enterprise Data Warehouse, which is a single, comprehensive and integrated repository of clinical and research data sources. The biopsies were locally reviewed for clinical care purposes and then also underwent an independent, blinded central review. Acute rejection (AR) was scored using the Banff Rejection Activity Index [14]. Clinical and histological data were reviewed by a transplant hepatologist (J.L.). Liver biopsies were categorized as: (1) AR if histology demonstrated evidence of acute rejection; (2) Non-Rejection: hyperbilirubinemia (NR:HBR) if serum total bilirubin was >2.5 mg/dL and there was no histologic evidence of rejection; (3) NR: normal or mild elevation in liver function tests (LFTs) (NR:Mild) if there was no histologic evidence of rejection, serum total bilirubin ≤2.5 mg/dL and alanine transaminase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) levels were ≤1.67 × upper limit of normal [15]; and (4) NR: others with non-HBR high LFTs (NR:Others) if there was no histologic evidence of acute rejection, but serum ALT, AST and ALP levels were >1.67 × upper limit of normal with total bilirubin ≤2.5 mg/dL. None of the donor livers in this study were donation after circulatory death (DCD). This study was approved by the Northwestern University Institutional Review Board (STU00213022).

RNA-seq analysis

Total RNA was isolated from liver biopsies using the RNeasy micro kit (Qiagen, Germantown, MD) according to the instructions of the manufacturer. RNA-seq was conducted at Northwestern University NUSeq Core Facility as recently described [16]. Briefly, total RNA samples were checked for quality using RNA integrity numbers (RINs) generated from the Agilent Bioanalyzer 2100. One sample failed QC (RIN<7) and was excluded from the study, therefore 19 samples proceeded to sequencing. RNA quantity was determined with Qubit fluorimeter. The Illumina TruSeq Stranded mRNA Library Preparation Kit was used to prepare sequencing libraries from 1 μg of high-quality RNA samples (RIN>7). This procedure includes mRNA purification and fragmentation, cDNA synthesis, 3’ end adenylation, Illumina adapter ligation, library PCR amplification and validation. An Illumina HiSeq 4000 sequencer was used to sequence the libraries with the production of single-end, 50 bp reads at the depth of 20–25 M reads per sample.

The quality of reads, in FASTQ format, was evaluated using FastQC. Reads were trimmed to remove Illumina adapters from the 3’ ends using cutadapt. Trimmed reads were aligned to the human genome (hg38) using STAR [17]. Read counts for each gene were calculated using htseq-count in conjunction with a gene annotation file for hg38 obtained from Ensembl (http://useast.ensembl.org/index.html). Normalization and differential expression were calculated using DESeq2 that employs the Wald test [18]. The cutoff for determining significantly differentially expressed genes was
an FDR-adjusted p-value less than 0.05 using the Benjamini–Hochberg method. Ranking of differentially expressed genes in NR:Mild and NR:HBR groups was performed using the EdgeR package in R studio version 1.2.1335 [19–21]. The normalized enrichment score for hallmark gene sets was then determined using gene set enrichment analysis (GSEA) software [22, 23]. In addition, data analysis was also performed using GeneCodis 4.0 to identify significant pathways among the significantly differentially expressed genes (https://genecodis.genyo.es/). A P-adj value < 0.05 was deemed to be statistically significant. Lastly, comparisons between serum liver chemistries (ALT, AST, total bilirubin and ALP) and hepatic gene expression data was preformed using Pearson Correlation test in PRISM 9 software (GraphPad, San Diego, CA). Statistical significance was defined as a P value of less than 0.05.

**Results**

Table 1 and Additional file 1 list the patient demographics, clinical information, biopsy category and steatosis levels as defined in Methods for nineteen patients. The timing between biopsy and liver transplant was 55.2 ± 10.7 months, with a range of 26 days to 12 years. Three patients had evidence of AR, while there was no histologic evidence of AR in the sixteen other liver biopsies. Of the NR groups, 3 patients were categorized as NR:HBR, 4 patients were categorized as NR:Mild, and 9 patients were categorized as NR:Others. The patients in the NR:Mild and NR:Others groups had serum total bilirubin levels that were ≤ 1.5 mg/dL. None of the samples in the AR and NR:HBR groups demonstrated steatosis. One of the samples in the NR_Mild group and two samples in the NR_Others group showed mild steatosis. One sample in the NR_Others group had moderate steatosis.

| Table 1 Patient characteristics |
|---------------------------------|
|                                | AR (n = 3) | NR:HBR (n = 3) | NR:Mild (n = 4) | NR:Others (n = 9) |
| Age at transplant (years, mean [range]) | 44 [20, 64] | 45 [27, 65] | 47 [26, 65] | 54 [25, 65] |
| Caucasian race (%)              | 3 (100)    | 3 (100)      | 3 (75)        | 7 (78)        |
| Male sex (%)                    | 1 (33)     | 2 (67)       | 3 (75)        | 4 (44)        |
| Primary liver diagnosis (%)     |            |              |               |               |
| Hepatitis C (non-viremic)       | 0 (0)      | 0 (0)        | 0 (0)         | 1 (11)        |
| Alcohol                         | 1 (33)     | 0 (0)        | 1 (25)        | 0 (0)         |
| Non-alcoholic fatty liver or cryptogenic | 1 (33)     | 0 (0)        | 1 (25)        | 3 (33)        |
| Immune-mediated (PSC, AIH, PBC) | 0 (0)      | 3 (100)      | 2 (50)        | 4 (44)        |
| Other                           | 1 (33)     | 0 (0)        | 0 (0)         | 1 (11)        |
| Months from LT (mean, [range])  | 8.0 [4.6, 10.2] | 44 [0.8, 71.5] | 82 [6.5, 119.1] | 63 [4.7, 142.5] |
| Immunosuppression (%)           |            |              |               |               |
| CNI therapy                     | 3 (100)    | 3 (100)      | 4 (100)       | 9 (100)       |
| Mycophenolic acid therapy       | 3 (100)    | 3 (100)      | 2 (50)        | 2 (22)        |
| Prednisone                      | 1 (33)     | 3 (100)      | 1 (25)        | 4 (44)        |
| Laboratory values (mean, [range]) |         |              |               |               |
| ALT (U/L)                       | 172 [68, 252] | 165 [27, 302] | 54 [20, 84] | 98 [22, 303] |
| AST (U/L)                       | 115 [27, 178] | 104 [50, 134] | 41 [18, 64] | 44 [22, 103] |
| Alkaline phosphatase (U/L)      | 146 [54, 226] | 264 [164, 366] | 100 [68, 130] | 363 [191, 621] |
| Total bilirubin (mg/dL)         | 1 [0.5, 1.2] | 8 [3.5, 12.2] | 1 [0.5, 1.5] | 1 [0.3, 1.5] |
| Rejection characteristics (%)   |            |              |               |               |
| Mild (RAI 3–4)                  | 1 (33)     | –            | –             | –             |
| Moderate–Severe (RAI 5–9)       | 2 (67)     | –            | –             | –             |
| Steatosis characteristics (%)   |            |              |               |               |
| None                            | 3 (100)    | 3 (100)      | 3 (75)        | 6 (67)        |
| Mild                            | 0 (0)      | 0 (0)        | 1 (25)        | 2 (22)        |
| Moderate                        | 0 (0)      | 0 (0)        | 0 (0)         | 1 (11)        |
| Severe                          | 0 (0)      | 0 (0)        | 0 (0)         | 0 (0)         |

AR acute rejection, NR:HBR non-rejection with hyperbilirubinemia (serum total bilirubin > 2.5 mg/dL), NR:Mild non-rejection; serum total bilirubin ≤ 2.5 mg/dL; ALT, AST and ALP ≤ 1.67 × ULN, NR:Others other non-rejection with serum total bilirubin ≤ 2.5 mg/dL; ALT, AST and ALP > 1.67 × ULN
Figure 1 depicts the principal component analysis (PCA) of RNA-seq data performed on the 19 samples. PCA analysis demonstrated that the 3 samples in the NR:HBR group clustered independently from all other samples. In contrast, samples from the 3 other categories did not cluster independently from any of the other groups.

Differential gene expression analysis comparing NR:HBR group to all other NR samples showed that 784 genes were differentially expressed. When comparing NR:HBR to NR:Mild, 977 genes were identified that differentially expressed between the 2 groups. Figure 2A is a volcano plot illustrating the top differentially expressed genes, among which the expression of CYP7A1 was significantly higher, while LOXL4, CFTR and ADGRG2 expression was lower in the NR:Mild group compared to NR:HBR. Subsequent GSEA study using the Hallmark pathway database demonstrated increased expression in apoptosis, inflammation and cell proliferation pathways in the NR:HBR group compared to NR:Mild (Fig. 2B). The Unfolded_Protein_Response pathway is also enriched in the NR:HBR group, having a normalized enrichment score of 1.431951, although the FDR q-value was 0.051 (Fig. 2C). Complementary pathway analysis using GeneCodis revealed that three UPR-related pathways were significantly upregulated in the NR:HBR group compared to NR:Mild (P-adj < 0.05): (1) response to unfolded protein, (2) endoplasmic reticulum unfolded protein response, and (3) negative regulation of PERK-mediated unfolded protein response (Table 2).

We next compared the RNA-seq expression of liver biopsies from the AR group to the NR groups. The PCA plot demonstrated that the AR group did not cluster independently from the NR groups (Fig. 1). Lymphocyte activating 3 (LAG3) and cyclin dependent kinase 1 (CDK1) genes had the greatest increase in expression in AR compared to NR groups as shown in the volcano plot (Fig. 3A). Although several additional genes had changes in gene expression level with a P < 0.05, only LAG3 and CDK1 had P-adj values less than 0.05. Figure 3B demonstrated that gene expression in the AR group was
approximately 2.4-fold and 3.4-fold higher, for LAG3 and CDK1, respectively compared to the NR groups.

We subsequently sought to determine, using all samples, if the level of the serum liver chemistries (ALT, AST, total bilirubin and ALP) correlated with the expression level of hepatic UPR genes. Table 3 lists the Pearson r and P values of the Pearson Correlation analysis comparing levels of serum ALT, AST and total bilirubin, with expression of the UPR genes from the XBP1, PERK and ATF6 pathways [24]. Additional files
2, 3 and 4 are the graphs of these data. Overall, one of the PERK pathway target genes, activating transcription factor 3 (ATF3) showed the highest correlations with aminotransferase levels ($r = 0.77$ with $p = 0.001$ for ALT, and $r = 0.68$ with $p = 0.001$ for AST), whereas ATF6 gene expression correlated most with total bilirubin ($r = 0.69$ with $p = 0.001$). Of note, no correlations were identified between serum ALP levels and the expression of liver UPR genes. Tables 4 and 5 list the Pearson $r$ and $P$ values comparing serum ALT, AST, ALP and total bilirubin to the expression of bile acid metabolism and inflammatory genes. Additional files 5 and 6 are the graphs of these data. Among genes tested, fibroblast growth factor 19 (FGF19) known to play a key role in regulating bile acid synthesis had the highest correlation with total bilirubin with $r$ of 0.96 ($p = 0.0001$). Two bile acid transporters genes, SLC51B encoding organic solute transporter beta and ABCB4 encoding ATP binding cassette subfamily B member 4 (also known as PFIC-3), correlated with all 4 serum liver chemistries. Of note, there was no correlation between CYP7A1 or NR1H4 (FXR) gene expression with any of the serum liver chemistries. Inflammatory gene FOXP3 expression had the highest correlation with total bilirubin ($r = 0.8283$, $p = 0.0001$) and it also correlated with ALT and AST.
In this study, we performed hepatic transcriptome analysis on human liver biopsies from post-liver transplantation patients. As expected, pathway analysis demonstrated increased expression of the hepatic inflammatory response, apoptosis, and cell proliferation pathways in the NR:HBR group compared to the NR:Mild group, which are the common pathways that are induced with liver injury. Most interestingly, pathway analysis also identified increased expression of the liver UPR pathways in the NR:HBR group compared to the NR:Mild group. It has been previously reported that selected UPR genes are down-regulated in PSC patients with a high risk of developing PSC-related complications [7]. Patients with progressive nonalcoholic steatohepatitis (NASH) also have UPR dysregulation and an attenuated UPR response compared to patients with benign hepatic steatosis [25], although this was not seen in other patient populations [26]. Similarly, weanling mice have an impaired ability to activate their hepatic XBP1 pathway, with a resultant increase in serum ALT, increased proapoptotic C/EBP homologous protein and death receptor 5 expression, and enhanced liver apoptosis [27]. Therefore, hepatic UPR activation may be a protective response to cholestatic liver injury, while an impaired or attenuated UPR response can lead to increased liver injury in both animal models of cholestasis and potentially human diseases such as PSC and NASH.

We next sought to determine the relationship between the levels of serum liver chemistries and expression of hepatic UPR genes. We identified significant correlations between serum ALT and AST with downstream gene targets of all three UPR pathways (XBP1, PERK and ATF6), and total bilirubin correlated with downstream targets of PERK and ATF6 pathways. Although these correlations do not imply a causative relationship, it is worth noting that there was a consistently positive relationship between increasing levels of these serum liver chemistries and increasing UPR gene expression. This finding further supports the relationship between increased ER stress and degree of hepatocellular injury and/or diminished hepatobiliary secretory function. Interestingly, there was no correlation between serum ALP and hepatic UPR target gene expression. This could be attributed to the fact that serum ALP level reflects its activity not only in the liver, but also from the bone and other tissues. While it is likely that the serum alkaline phosphatase was of liver origin and alkaline phosphatase fractionation was not available, it is derived mainly from cholangiocytes rather than hepatocytes.

Although comparing the AR group with the NR groups did not reveal independent gene clustering or altered gene expression of UPR pathways, the AR group had significantly increased gene expression of LAG3 and CDK1. LAG3 is highly expressed in activated T-lymphocytes, and the increased expression that we observed using bulk RNA-seq may be due to intrahepatic T-lymphocyte

| Table 4 Pearson correlation analysis of serum liver chemistries and hepatic bile acid metabolism gene expression |
|---------------------------------------------------------------|
| **Gene**          | **Pearson r** | **P value** |
|-------------------|---------------|-------------|
| Correlated with ALT |               |             |
| SLC51B           | 0.6562        | 0.0023      |
| ABCB4            | 0.6548        | 0.0035      |
| SLCO1B1          | −0.5436       | 0.016       |
| FGF19            | 0.6408        | 0.0031      |
| Correlated with AST |             |             |
| SLC51B           | 0.5846        | 0.0086      |
| ABCB4            | 0.5729        | 0.0104      |
| SLCO1B1          | −0.5458       | 0.0156      |
| FGF19            | 0.5148        | 0.0241      |
| Correlated with ALP |            |             |
| SLC51B           | 0.4799        | 0.0376      |
| ABCB4            | 0.5087        | 0.0262      |
| Correlated with total bilirubin |       |             |
| SLC51A           | 0.6292        | 0.0039      |
| SLC51B           | 0.7521        | 0.0002      |
| ABCB4            | 0.5474        | 0.0153      |
| FGF19            | 0.9583        | 0.0001      |

| Table 5 Pearson correlation analysis of serum liver chemistries and hepatic inflammation gene expression |
|---------------------------------------------------------------|
| **Gene**          | **Pearson r** | **P value** |
|-------------------|---------------|-------------|
| Correlated with ALT |               |             |
| CD163             | 0.5149        | 0.0241      |
| FOXP3             | 0.6089        | 0.0057      |
| CCL2              | 0.4971        | 0.0304      |
| Correlated with AST |             |             |
| IFNG              | 0.4563        | 0.0495      |
| CD163             | 0.6388        | 0.0032      |
| ICAM1             | 0.5384        | 0.0174      |
| FOXP3             | 0.5474        | 0.0153      |
| CCL2              | 0.4888        | 0.0337      |
| CD3D              | 0.4624        | 0.0462      |
| CD8A              | 0.4831        | 0.0362      |
| Correlated with total bilirubin |       |             |
| FOXP3             | 0.8283        | 0.0001      |
| CCL2              | 0.5469        | 0.0154      |

**Discussion**

In this study, we performed hepatic transcriptome analysis on human liver biopsies from post-liver transplantation patients. As expected, pathway analysis
activation rather than enhanced expression in primary liver parenchyma. ER stress-induced hepatic cell injury could also generate immunostimulating signals activating lymphocytes, which could be further confirmed using animal models in future studies. Single cell or single-nuclei RNA-seq provides more in-depth information on cell-specific gene expression, however our samples were stored in RNAlater and not suitable for such experiments. In addition, the increased expression of CDK1, a key gene in cell cycle, in the AR group is likely due to enhanced cell proliferation that can occur in response to hepatic injury. There were a relatively small number of patients with acute rejection, and it is possible that other associations can be identified using a larger patient population [28–30].

In this post-transplantation study, we defined our cholestasis patient group, independent of their pre-transplantation etiology, using serum total bilirubin rather than serum bile acid levels since serum bile acid levels were not routinely obtained in our patient groups. It is well accepted that one of the major factors causing cholestatic liver injury is increased hepatocellular bile acid concentrations, hydrophobicity and/or a total bile acid pool. Animal studies using bile acid toxicity models have demonstrated that cholestasis induces ER stress and UPR activation [8, 27].

Of note, induction of hepatic ER stress in cholestasis decreases gene expression of Cyp7a1, Fxr, Abcc3 and Abcb11 similar to the pattern observed in our study [31, 32]). These hepatic changes can reduce bile acid synthesis and increase bile acid efflux transporters, which are protective responses to reduced hepatocellular bile acid toxicity. There are additional causes of serum bilirubin elevations including increased bilirubin formation from severe internal bleeding, multiple blood transfusions, hemolysis or dyserythropoiesis. However, there was no evidence for these alternate etiologies in our patient cohort. Of note, transplantation using a DCD donor is associated with ischemic cholangiopathy, which could alter gene expression. None of the samples in this study is DCD liver, which excludes this potential complication.

One limitation of the current study is the relatively small sample size given the availability of the biobanked tissues, therefore future studies with a larger cohort are needed to validate our findings. The liver biopsy specimens utilized for the study were from a patient population with previous liver transplantation, obtained for-cause but otherwise in an unbiased manner. It is possible that immunosuppressive and other medica-tions could potentially affect hepatic gene expres-sion. Therefore, it would be interesting to extend these observations using liver biopsies from other patient populations. Since these are allograft biopsies, donor characteristics may play an important role. Although donor information is unavailable for these samples, our study comparing the transcriptome profile in different patient groups is still valid.

**Conclusions**

A growing literature of murine data has demonstrated the causative relationship between cholestasis, and ER stress with UPR activation, with a paucity of data in human populations. Our liver biopsy transcriptome data provide a novel demonstration of an association between human hepatic UPR gene expression and human cholestasis.

**Abbreviations**

PBC: Primary biliary cholangitis; PSC: Primary sclerosing cholangitis (PSC); UPR: Unfolded protein response; ER: Endoplasmic reticulum; XBP1: X-box binding protein 1; PERK: PKR-like ER kinase; ATF6: Activating transcription factor 6; AR: Acute rejection; NR: Non-rejection; LFT: Liver function test; HBR: Hyperbilirubinem; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; DCD: Donation after circulatory death; RIN: RNA integrity number; GSEA: Gene set enrichment analysis; PCA: Principal component analysis; LAG3: Lymphocyte activating 3; CDK1: Cyclin dependent kinase 1; ATF3: Activating transcription factor 3; FGF19: Fibroblast growth factor 19; NASH: Nonalcoholic steatohepatitis.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12876-022-02459-8.

**Additional file 1.** Individual patient characteristics.

**Additional file 2.** Hepatic unfolded protein response gene expression correlated with serum ALT.

**Additional file 3.** Hepatic unfolded protein response gene expression correlated with serum AST.

**Additional file 4.** Hepatic unfolded protein response gene expression correlated with serum total bilirubin.

**Additional file 5.** Hepatic bile acid metabolism gene expression correlated with serum liver chemistries.

**Additional file 6.** Hepatic inflammation gene expression correlated with serum liver chemistries.

**Acknowledgements**

The authors wish to thank the Northwestern University Center of Genetic Medicine NUSeq core facility for performing RNA-seq and for assistance in bioinformatics analysis.

**Author contributions**

XL, JL and RMG designed the study. SC screened the samples. XL performed the RNA extraction. XL and SAT analyzed the data. XL and RMG wrote the draft. SC, SAT and JL edited the draft. All authors read and approved the final manuscript.

**Funding**

Northwestern Medicine Digestive Health Foundation (XL, RMG); NIDDK R01DK121997, NIDDK R01DK093807, Max Goldenberg Foundation, George Lockerbie Liver Cancer Foundation (RMG), NIDDK 1K08DK121937 (SAT). The funding bodies have no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Availability of data and materials
RNA-seq data has been deposited to GEO (accession number GSE203453). Other data generated or analyzed during this study are included in this published article and its additional files.

Declarations

Ethics approval and consent to participate
This study was approved by the Northwestern University Institutional Review Board (STU00213022). Informed consent was obtained from all subjects involved in the present study. All methods were carried out in accordance with relevant guidelines and regulations.

Consent for publication
Not applicable.

Competing interests
JL is a consultant for Eurofins/Viracor/Transplant Genomics and Novartis. There are no competing interest for other authors.

Author details
1 Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
2 Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, USA.

Received: 20 May 2022   Accepted: 30 July 2022
Published online: 10 August 2022

References
1. de Vries E, Beuers U. Management of cholestatic disease in 2017. Liver Int. 2017;37(Suppl 1):123–9.
2. Kriegermeier A, Green R. Pediatric cholestatic liver disease: review of bile acid metabolism and discussion of current and emerging therapies. Front Med. 2020;7:1149.
3. Fosby B, Karlsten TH, Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol. 2012;18(1):1–15.
4. Steenstraaten IC, Sebib Korkmaz K, Trivedi PJ, Inderson A, van Hoek B, Rodriguez Girondo MDM, et al. Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation. Aliment Pharmacol Ther. 2019;49(6):636–43.
5. Tanaka A, Kono H, Leung PSC, Gershwin ME. Recurrence of disease following organ transplantation in autoimmune liver disease and systemic lupus erythematosus. Cell Immunol. 2020;347:104021.
6. Carbone M, Neuberger J. Liver transplantation in PBC and PSC: indications and disease recurrence. Clin Res Hepatol Gastroenterol. 2011;35(6–7):464–56.
7. Gindin Y, Chung C, Jiang Z, Zhou JZ, Xu J, Billin AN, et al. A fibrosis-independent hepatic transcriptomic signature identifies drivers of disease progression in primary sclerosing cholangitis. Hepatology. 2021;73(3):1105–16.
8. Liu X, Guo GL, Kong B, Hilburn DB, Hubchak SC, Park S, et al. Farnesoid X receptor signaling activates the hepatic X-box binding protein 1 pathway in vitro and in vivo. Hepatology. 2018;68(1):304–16.
9. Liu X, Green RM. Endoplasmic reticulum stress and liver diseases. Liver Res. 2019;3(1):55–64.
10. Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. J Hepatol. 2011;54(4):795–809.
11. Henkel A, Green RM. The unfolded protein response in fatty liver disease. Semin Liver Dis. 2013;33(3):321–9.
12. Almanza A, Carlesso A, Chinthu C, Creedican D, Doultosinos D, Leuzzi B, et al. Endoplasmic reticulum stress signalling—from basic mechanisms to clinical applications. FEBS J. 2019;286(2):241–78.
13. Ron D, Walter P Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007;8(7):519–29.
14. Horoldt BS, Burattin M, Gunson BK, Bramhall SR, Nightingale P, Hubscher SG, et al. Does the Banff rejection activity index predict outcome in patients with early acute cellular rejection following liver transplantation? Liver Transpl. 2006;12(7):1144–51.
15. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowls L, Invernizzi P, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631–43.
16. Liu X, Taylor SA, Gromer KD, Zhang D, Hubchak SC, LeCuyer BE, et al. Mechanisms of liver injury in high fat sugar diet fed mice that lack hepatocyte X-box binding protein 1. PLoS ONE. 2022;17(1):e0261789.
17. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR ultrafast universal RNA-seq aligner. Bioinformat.ics. 2013;29(1):15–21.
18. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
19. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009;26(1):139–40.
20. McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multi-factor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res. 2012;40(10):4288–97.
21. Chen Y, Lun ATL, Smyth GK. From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using RiboSeq and the edgeR quasi-likelihood pipeline [version 2; peer review: 5 approved]. F1000 research. 2016;5:1438–.
22. Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Shag S, Lehr J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267–73.
23. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102(43):15545–50.
24. Grandjean JMD, Madhavan A, Cech L, Seguinot BO, Paxman RJ, Smith E, et al. Pharmacologic IRE1α/XBP1 activation confers targeted ER proteinostasis reprogramming. Nat Chem Biol. 2020;16(10):1052–61.
25. Puri P, Mirshahi F, Cheung Q, Natarajan R, Maher JW, Kellum JM, et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology. 2008;134(2):568–76.
26. Kim RS, Hasegawa D, Goossens N, Tuchida T, Athwal V, Sun X, et al. The XBP1 arm of the unfolded protein response induces fibrogenic activity in hepatic stellate cells through autophagy. Sci Rep. 2016;6:39342.
27. Kriegermeier A, Hyon A, Sommer M, Hubchak S, LeCuyer B, Liu X, et al. Hepatic X-Box binding protein 1 and unfolded protein response is impaired in weanling mice with resultant hepatic injury. Hepatology. 2021;74(6):3362–75.
28. Levitsky J, Kandelpal M, Guo K, Zhao L, Kurian S, Whisenant T, et al. Prediction of liver transplant rejection with a biologically relevant gene expression signature. Transplantation. 2022;106:1004–11.
29. Morita M, Chen J, Fujino M, Kitazawa Y, Sugioka A, Zhong L, et al. Identification of microRNAs involved in acute rejection and spontaneous tolerance in murine hepatic allografts. Sci Rep. 2014;4(1):6649.
30. Lee NP, Wu H, Ng KTP, Luo R, Lam TW, Lo CM, et al. Transcriptome analysis of acute phase liver graft injury in liver transplantation. Biomedicines. 2018;6(2):41.
31. Henkel AS, LeCuyer B, Olivares S, Green RM. Endoplasmic reticulum stress regulates hepatic bile-acid metabolism in mice. Cell Mol Gastroenterol Hepatol. 2017;3(2):261–71.
32. Guo G. Endoplasmic reticulum stress emerges as novel regulator for bile acid synthesis. Cell Mol Gastroenterol Hepatol. 2017;3(2):135.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.